FilingSEC EDGAR8-K
Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation for AP-SA02
· SEC accepted
StagePhase 3 Preparation
Filing content
Armata Pharmaceuticals announced that the FDA granted Breakthrough Therapy designation to its AP-SA02 product candidate for the treatment of complicated Staphylococcus aureus bacteremia.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…